Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results

BACKGROUND: Tiotropium is a once-daily, long-acting anticholinergic bronchodilator with the potential to alleviate airway obstruction in cystic fibrosis. Our objective was to evaluate the efficacy and safety of 2.5 and 5 µg once-daily tiotropium delivered via the Respimat Soft Mist Inhaler vs. place...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradley, Judy M., Koker, Paul, Deng, Qiqi, Moroni-Zentgraf, Petra, Ratjen, Felix, Geller, David E., Elborn, J. Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154718/
https://www.ncbi.nlm.nih.gov/pubmed/25188297
http://dx.doi.org/10.1371/journal.pone.0106195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154718/
https://www.ncbi.nlm.nih.gov/pubmed/25188297
http://dx.doi.org/10.1371/journal.pone.0106195

Ejemplares similares